K. L. Blackwell

562 total citations
16 papers, 438 citations indexed

About

K. L. Blackwell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, K. L. Blackwell has authored 16 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in K. L. Blackwell's work include HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (4 papers) and Advanced Breast Cancer Therapies (3 papers). K. L. Blackwell is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (4 papers) and Advanced Breast Cancer Therapies (3 papers). K. L. Blackwell collaborates with scholars based in United States, Netherlands and South Korea. K. L. Blackwell's co-authors include María Koehler, Mark L. Urken, Hugh F. Biller, Gloria Broadwater, Mark W. Dewhirst, J. O’Shaughnessy, Harold J. Burstein, José Baselga, Allison Florance and A. M. Storniolo and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

K. L. Blackwell

15 papers receiving 419 citations

Peers

Countries citing papers authored by K. L. Blackwell

Since Specialization

Citations

This map shows the geographic impact of K. L. Blackwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. L. Blackwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. L. Blackwell more than expected).

Fields of papers citing papers by K. L. Blackwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. L. Blackwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. L. Blackwell. The network helps show where K. L. Blackwell may publish in the future.

Co-authorship network of co-authors of K. L. Blackwell

This figure shows the co-authorship network connecting the top 25 collaborators of K. L. Blackwell. A scholar is included among the top collaborators of K. L. Blackwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. L. Blackwell. K. L. Blackwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3 2016 ·Clinical Cancer Research ·PA Fasching, Guy Jérusalem, Xavier Pivot, Marta Gil-Martín, Michelino De Laurentiis, K. L. Blackwell, Francisco J. Esteva, (unknown), Zhenrong Tang, Karen Rodriguez Lorenc, Dennis J. Slamon	3
2	LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2 2016 ·Annals of Oncology ·Yoon Sim Yap, (unknown), K. L. Blackwell, David Cameron, Serene S. Foo, Virote Sriuranpong, (unknown), (unknown), T.-Y. Kim, (unknown), (unknown), (unknown), (unknown), Jae Hyoung Kim, Ming‐Feng Hou, (unknown), Farida Souami, Shyeilla V. Dhuria, Marshall G. Miller, Sunil Verma	7
3	Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification 2012 ·British Journal of Cancer ·Allison Betof Warner, Zahid N. Rabbani, Matthew E. Hardee, (unknown), Gloria Broadwater, Rex C. Bentley, Shane A. Snyder, Z. Vujaskovic, Egbert Oosterwijk, Lyndsay N. Harris, Janet K. Horton, Mark W. Dewhirst, K. L. Blackwell	41
4	TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). 2011 ·Journal of Clinical Oncology ·Ayca Gucalp, SM Tolaney, SJ Isakoff, J. N. Ingle, (unknown), LA Carey, K. L. Blackwell, H. S. Rugo, Lisle Nabell, A. Abbruzzi, José González, D. D. Giri, (unknown), (unknown), Gabriella D’Andrea, (unknown), Pamela Drullinsky, Nancy T. Sklarin, C. Hudis, (unknown)	4
5	AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome. 2011 ·Journal of Clinical Oncology ·Bárbara Adamo, (unknown), (unknown), Emily Burrows, Karen Fritchie, K. L. Blackwell, Erika Hamilton, Joseph Geradts, Leigh B. Thorne, Andrey Ugolkov, (unknown), Matthew G. Ewend, LA Carey, Charles M. Perou, Vincent L. Cryns, (unknown)	0
6	SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). 2010 ·Journal of Clinical Oncology ·K. L. Blackwell, Erika Hamilton, Gifone Aguiar Rocha, (unknown), (unknown), Kouros Motamed, (unknown), L H Hwang, (unknown), Neil Desai	6
7	Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy. 2010 ·Journal of Clinical Oncology ·Sunil Badve, (unknown), Mangesh A. Thorat, Robert Gagnon, Catherine Ellis, Joyce O’Shaughnessy, K. L. Blackwell, José Baselga, G. W. Sledge	1
8	Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). 2010 ·Journal of Clinical Oncology ·Erika Hamilton, (unknown), Neil Desai, Sandeep Singh, Judith O. Hopkins, P. Kelly Marcom, Vijaya Chadaram, Richard Welch, (unknown), K. L. Blackwell	6
9	Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study 2009 ·Journal of Clinical Oncology ·Ramona F. Swaby, K. L. Blackwell, Zefei Jiang, Yan Sun, Véronique Dièras, Khalil Zaman, Charles Zacharchuk, C. Thomas Powell, (unknown), Manisha Thakuria	73
10	Analysis of dermatologic events in patients with cancer treated with lapatinib 2008 ·Breast Cancer Research and Treatment ·Mario E. Lacouture, (unknown), María Koehler, Robert Sweetman, A. Preston, Angelo Di Leo, Henry Gómez, Vanessa Salazar, Julie Byrne, Kevin M. Koch, K. L. Blackwell	73
11	A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy 2008 ·Journal of Clinical Oncology ·J. O’Shaughnessy, K. L. Blackwell, Harold J. Burstein, A. M. Storniolo, G. W. Sledge, José Baselga, María Koehler, (unknown), Allison Florance, (unknown)	109
12	Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009 2008 ·Journal of Clinical Oncology ·Bella Kaufman, Maureen Trudeau, S. Johnston, Ahmad Awada, K. L. Blackwell, Thomas Bachelot, Vanessa Salazar, Ronald Westlund, Michelle DeSilvio, Tal Zaks	5
13	Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. 2000 ·PubMed ·K. L. Blackwell, Zishan A. Haroon, (unknown), (unknown), Gloria Broadwater, C S Greenberg, Mark W. Dewhirst	65
14	Reconstruction of the Laryngopharynx After Hemicricoid/Hemithyroid Cartilage Resection: Preliminary Functional Results 1997 ·Archives of Otolaryngology - Head and Neck Surgery ·Mark L. Urken, K. L. Blackwell, Hugh F. Biller	41
15	Space shuttle afterbody aerodynamics/plume simulation data summary 1978 ·NASA STI Repository (National Aeronautics and Space Administration) ·K. L. Blackwell, (unknown)	3
16	Effect of gaseous and solid simulated jet plumes on an 040A space shuttle launch configuration at m=1.6 to 2.2 1974 ·NASA STI Repository (National Aeronautics and Space Administration) ·(unknown), (unknown), (unknown), K. L. Blackwell, John P. Decker, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact